The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study
Abstract
Objective: L‐dopa is the most widely used and most effective therapy for Parkinson disease (PD), but chronic treatment is associated with motor complications in the majority of patients. It has been hypothesized that providing more continuous delivery of L‐dopa to the brain would reduce the risk of motor complications, and that this might be accomplished by combining L‐dopa with entacapone, an inhibitor of catechol‐O‐methyltransferase, to extend its elimination half‐life. Methods: We performed a prospective 134‐week double‐blind trial comparing the risk of developing dyskinesia in 747 PD patients randomized to initiate L‐dopa therapy with L‐dopa/carbidopa (LC) or L‐dopa/carbidopa/entacapone (LCE), administered 4× daily at 3.5‐hour intervals. The primary endpoint was time to onset of dyskinesia. Results: In comparison to LC, patients receiving LCE had a shorter time to onset of dyskinesia (hazard ratio, 1.29; p = 0.04) and increased frequency at week 134 (42% vs 32%; p = 0.02). These effects were more pronounced in patients receiving dopamine agonists at baseline. Time to wearing off and motor scores were not significantly different, but trended in favor of LCE treatment. Patients in the LCE group received greater L‐dopa dose equivalents than LC‐treated patients (p < 0.001). Interpretation: Initiating L‐dopa therapy with LCE failed to delay the time of onset or reduce the frequency of dyskinesia compared to LC. In fact, LCE was associated with a shorter time to onset and increased frequency of dyskinesia compared to LC. These results may reflect that the treatment protocol employed did not provide continuous L‐dopa availability and the higher L‐dopa dose equivalents in the LCE group. ANN NEUROL 2010;68:18–27
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Predictive reward signal of dopamine neurons
Schultz, W. (1998) · Journal of Neurophysiology · doi:10.1152/jn.1998.80.1.1 · Cited by 4,564
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
Self-citationGrace, A. A. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90196-u · Cited by 1,831
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Self-citationThe scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Self-citationThe control of firing pattern in nigral dopamine neurons: single spike firing
Grace, A., & Bunney, B. (1984) · The Journal of Neuroscience · doi:10.1523/jneurosci.04-11-02866.1984 · Cited by 858
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Self-citationPramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY
Marsden, C. D., & Parkes, J. D. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91416-1 · Cited by 661
Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70521-x · Cited by 547
Self-citationLevodopa motor complications in Parkinson's disease
Obeso, J. A., Olanow, C. W., & Nutt, J. G. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00031-8 · Cited by 478
Self-citationde la Fuente-Fernandez, R. (2004) · Brain · doi:10.1093/brain/awh290 · Cited by 402
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
Rinne, U. K., Larsen, J. P., Siden, A., Worm-Petersen, J., & The Nomecomt Study Group* (1998) · Neurology · doi:10.1212/wnl.51.5.1309 · Cited by 326
Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients
(1997) · Annals of Neurology · doi:10.1002/ana.410420511 · Cited by 308
(2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<2::aid-ana2>3.0.co;2-b · Cited by 249
Nutt, J. G., Woodward, W. R., Beckner, R. M., Stone, C. K., Berggren, K., Carter, J. H., Gancher, S. T., Hammerstad, J. P., & Gordin, A. (1994) · Neurology · doi:10.1212/wnl.44.5.913 · Cited by 247
Stocchi, F., Vacca, L., Ruggieri, S., & Olanow, C. W. (2005) · Archives of Neurology · doi:10.1001/archneur.62.6.905 · Cited by 229
Self-citationDuodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome
Antonini, A., Isaias, I. U., Canesi, M., Zibetti, M., Mancini, F., Manfredi, L., Dal Fante, M., Lopiano, L., & Pezzoli, G. (2007) · Movement Disorders · doi:10.1002/mds.21500 · Cited by 217
Koller, W. C., Hutton, J. T., Tolosa, E., Capilldeo, R., & the Carbidopa/Levodopa Study Group (1999) · Neurology · doi:10.1212/wnl.53.5.1012 · Cited by 200
Self-citationAdherence to antiparkinson medication in a multicenter European study
Grosset, D., Antonini, A., Canesi, M., Pezzoli, G., Lees, A., Shaw, K., Cubo, E., Martinez‐Martin, P., Rascol, O., Negre‐Pages, L., et al. (2009) · Movement Disorders · doi:10.1002/mds.22112 · Cited by 171
Self-citationThe Scientific Basis for the Current Treatment of Parkinson's Disease
Olanow, C. W. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104422 · Cited by 170
Self-citationDevelopment of dyskinesias in a 5‐year trial of ropinirole and L ‐dopa
Rascol, O., Brooks, D. J., Korczyn, A. D., Deyn, P. P. D., Clarke, C. E., Lang, A. E., & Abdalla, M. (2006) · Movement Disorders · doi:10.1002/mds.20988 · Cited by 161
Self-citationDrug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease
Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0222 · Cited by 161
Self-citationKurth, M., Tetrud, J. W., Tanner, C. M., Irwin, I., Stebbins, G. T., Goetz, C. G., & Langston, J. (1993) · Neurology · doi:10.1212/wnl.43.9.1698 · Cited by 145
Miller, D. W., & Abercrombie, E. D. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.721516.x · Cited by 138
Hauser, R. A., Panisset, M., Abbruzzese, G., Mancione, L., Dronamraju, N., Kakarieka, A., & on behalf of the FIRST‐STEP Study Group (2008) · Movement Disorders · doi:10.1002/mds.22343 · Cited by 122
Long‐term duodenal infusion of levodopa for motor fluctuations in parkinsonism
Sage, J. I., Trooskin, S. Z., Sonsalla, P. K., Heikkila, R. E., & Duvoisin, R. C. (1988) · Annals of Neurology · doi:10.1002/ana.410240116 · Cited by 120
Horn, G. V., Schiess, M. C., & Koller, W. C. (2000) · Neurology · doi:10.1212/wnl.55.1.156 · Cited by 119
Smith, L. A., Jackson, M. J., Al‐Barghouthy, G., Rose, S., Kuoppamäki, M., Olanow, C. W., & Jenner, P. G. (2004) · Movement Disorders · doi:10.1002/mds.20317 · Cited by 113
Self-citationSmith, L. A., Jackson, M. J., Al‐Barghouthy, G., Rose, S., Kuoppamäki, M., Olanow, C. W., & Jenner, P. G. (2005) · Movement Disorders · doi:10.1002/mds.20421 · Cited by 112
Self-citationTen years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease
Syed, N. A., Murphy, J., Zimmerman, T. R., Mark, M. H., & Sage, J. I. (1998) · Movement Disorders · doi:10.1002/mds.870130222 · Cited by 94
Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease
Nutt, J. G., Carter, J. H., Lea, E. S., & Woodward, W. R. (1997) · Movement Disorders · doi:10.1002/mds.870120304 · Cited by 93
Smith, L. A., Jackson, M. J., Hansard, M. J., Maratos, E. C., & Jenner, P. G. (2003) · Movement Disorders · doi:10.1002/mds.10394 · Cited by 86
Impact of pramipexole on the onset of levodopa‐related dyskinesias
Constantinescu, R., Romer, M. M., McDermott, M., Kamp, C., & Kieburtz, K. (2007) · Movement Disorders · doi:10.1002/mds.21292 · Cited by 74
Self-citationZubair, M., Jackson, M. J., Tayarani‐Binazir, K. A., Stockwell, K., Smith, L. A., Rose, S., Olanow, W. C., & Jenner, P. G. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.002 · Cited by 24
Cited by
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Self-citationFox, S. H., Katzenschlager, R., Lim, S., Barton, B., de Bie, R. M. A., Seppi, K., Coelho, M., Sampaio, C., & on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee (2018) · Movement Disorders · doi:10.1002/mds.27372 · Cited by 1,002
Fox, S. H., Katzenschlager, R., Lim, S., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C. G., & Sampaio, C. (2011) · Movement Disorders · doi:10.1002/mds.23829 · Cited by 523
Self-citationWarren Olanow, C., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A. H., Emre, M., Nissinen, H., Leinonen, M., Stocchi, F., & Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) Investigators (2013) · Movement Disorders · doi:10.1002/mds.25364 · Cited by 484
Self-citationAn update on the diagnosis and treatment of Parkinson disease
Rizek, P., Kumar, N., & Jog, M. S. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.151179 · Cited by 447
Metadata
- Authors
- Stocchi, F., Rascol, O., Kieburtz, K., Poewe, W., Jankovic, J., Tolosa, E., Barone, P., Lang, A. E., & Olanow, C. W.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-06-25
- Volume
- 68
- Issue
- 1
- Pages
- 18-27
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1973698406
- Cited by
- 374
- References
- 36
- FWCI
- 18.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.